Lidia Wrobel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lidia Wrobel has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- David C. Rubinsztein
University of Cambridge
8 shared publications - Agnieszka Chacinska
IMol Polish Academy of Sciences, Warsaw, Poland
6 shared publications Eleanna Stamatakou
Department of Medical Genetics, and Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK
4 shared publications- Ulrike Topf
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland
4 shared publications - Sung Min Son
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
3 shared publications Agnieszka Chacinska
International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
- 29 August 2024
- Published by Springer Nature in Nature Cell Biology
- Vol. 26 (10) , 1691-1699
Nuclear proteasomes buffer cytoplasmic proteins during autophagy compromise
Autophagy is a conserved pathway where cytoplasmic contents are engulfed by autophagosomes, which then fuse with lysosomes enabling their degradation. Mutations in core autophagy genes cause neurological conditions, and autophagy defects are seen in neurodegenerative diseases such as Parkinson’s disease and Huntington’s disease. Thus, we have sought to understand the cellular pathway perturbations that autophagy-perturbed cells are vulnerable to by seeking negative genetic interactions such as synthetic lethality in autophagy-null human cells using available data from yeast screens. These revealed that loss of proteasome and nuclear pore complex components cause synergistic viability changes akin to synthetic fitness loss in autophagy-null cells. This can be attributed to the cytoplasm-to-nuclear transport of proteins during autophagy deficiency and subsequent degradation of these erstwhile cytoplasmic proteins by nuclear proteasomes. As both autophagy and cytoplasm-to-nuclear transport are defective in Huntington’s disease, such cells are more vulnerable to perturbations of proteostasis due to these synthetic interactions.
- 29 August 2024
- Published by Springer Nature in Nature Cell Biology
- Vol. 26 (10) , 1691-1699
Open AccessNuclear proteasomes buffer cytoplasmic proteins during autophagy compromise
Autophagy is a conserved pathway where cytoplasmic contents are engulfed by autophagosomes, which then fuse with lysosomes enabling their degradation. Mutations in core autophagy genes cause neurological conditions, and autophagy defects are seen in neurodegenerative diseases such as Parkinson’s disease and Huntington’s disease. Thus, we have sought to understand the cellular pathway perturbations that autophagy-perturbed cells are vulnerable to by seeking negative genetic interactions such as synthetic lethality in autophagy-null human cells using available data from yeast screens. These revealed that loss of proteasome and nuclear pore complex components cause synergistic viability changes akin to synthetic fitness loss in autophagy-null cells. This can be attributed to the cytoplasm-to-nuclear transport of proteins during autophagy deficiency and subsequent degradation of these erstwhile cytoplasmic proteins by nuclear proteasomes. As both autophagy and cytoplasm-to-nuclear transport are defective in Huntington’s disease, such cells are more vulnerable to perturbations of proteostasis due to these synthetic interactions.
- Open Access
- 3 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (18) , eadl6082
p37 regulates VCP/p97 shuttling and functions in the nucleus and cytosol
The AAA + -ATPase valosin-containing protein (VCP; also called p97 or Cdc48), a major protein unfolding machinery with a variety of essential functions, localizes to different subcellular compartments where it has different functions. However, the processes regulating the distribution of VCP between the cytosol and nucleus are not understood. Here, we identified p37 (also called UBXN2B) as a major factor regulating VCP nucleocytoplasmic shuttling. p37-dependent VCP localization was crucial for local cytosolic VCP functions, such as autophagy, and nuclear functions in DNA damage repair. Mutations in VCP causing multisystem proteinopathy enhanced its association with p37, leading to decreased nuclear localization of VCP, which enhanced susceptibility to DNA damage accumulation. Both VCP localization and DNA damage susceptibility in cells with such mutations were normalized by lowering p37 levels. Thus, we uncovered a mechanism by which VCP nucleocytoplasmic distribution is fine-tuned, providing a means for VCP to respond appropriately to local needs.
- 3 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (18) , eadl6082
Open Accessp37 regulates VCP/p97 shuttling and functions in the nucleus and cytosol
The AAA + -ATPase valosin-containing protein (VCP; also called p97 or Cdc48), a major protein unfolding machinery with a variety of essential functions, localizes to different subcellular compartments where it has different functions. However, the processes regulating the distribution of VCP between the cytosol and nucleus are not understood. Here, we identified p37 (also called UBXN2B) as a major factor regulating VCP nucleocytoplasmic shuttling. p37-dependent VCP localization was crucial for local cytosolic VCP functions, such as autophagy, and nuclear functions in DNA damage repair. Mutations in VCP causing multisystem proteinopathy enhanced its association with p37, leading to decreased nuclear localization of VCP, which enhanced susceptibility to DNA damage accumulation. Both VCP localization and DNA damage susceptibility in cells with such mutations were normalized by lowering p37 levels. Thus, we uncovered a mechanism by which VCP nucleocytoplasmic distribution is fine-tuned, providing a means for VCP to respond appropriately to local needs.
- Open Access
- 16 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-19
Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance
Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodegenerative diseases, especially Huntington’s disease and various spinocerebellar ataxias. Ideally, such approaches should preferentially clear the mutant/misfolded species, while having minimal impact on the stability of wild-type/normally-folded proteins. Furthermore, activation of both ubiquitin-proteasome and autophagy-lysosome routes may be advantageous, as this would allow effective clearance of both monomeric and oligomeric species, the latter which are inaccessible to the proteasome. Here we find that compounds that activate the D1 ATPase activity of VCP/p97 fulfill these requirements. Such effects are seen with small molecule VCP activators like SMER28, which activate autophagosome biogenesis by enhancing interactions of PI3K complex components to increase PI(3)P production, and also accelerate VCP-dependent proteasomal clearance of such substrates. Thus, this mode of VCP activation may be a very attractive target for many neurodegenerative diseases.
- 16 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-19
Open AccessCompounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance
Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodegenerative diseases, especially Huntington’s disease and various spinocerebellar ataxias. Ideally, such approaches should preferentially clear the mutant/misfolded species, while having minimal impact on the stability of wild-type/normally-folded proteins. Furthermore, activation of both ubiquitin-proteasome and autophagy-lysosome routes may be advantageous, as this would allow effective clearance of both monomeric and oligomeric species, the latter which are inaccessible to the proteasome. Here we find that compounds that activate the D1 ATPase activity of VCP/p97 fulfill these requirements. Such effects are seen with small molecule VCP activators like SMER28, which activate autophagosome biogenesis by enhancing interactions of PI3K complex components to increase PI(3)P production, and also accelerate VCP-dependent proteasomal clearance of such substrates. Thus, this mode of VCP activation may be a very attractive target for many neurodegenerative diseases.
- 31 January 2022
- Published by Royal Society of Chemistry (RSC)
- p. 14-23
Role of Academia: Drug Repurposing to Induce Autophagy for Treatment of Neurodegenerative Diseases
The prevalence of neurodegenerative diseases is increasing as the global population ages, and currently none of these late-onset conditions are curable. Therefore, there is an urgent need to understand the mechanisms of disease progression and to find new therapies. Most late-onset neurodegenerative disorders manifest with toxic, aggregate-prone proteins in neurons. Many of these harmful proteins have been shown to be autophagic substrates, and the induction of autophagy reduces their levels and attenuates disease phenotypes in neurodegenerative disease animal models. We and others have examined if existing drugs can be repurposed as new therapeutic agents that induce autophagy to reduce the levels of such toxic proteins. We highlight that a key component of a repurposing project is to test if the drug exposures at conventional doses in humans enable induction of the novel potentially therapeutic repurposing pathway.
- 31 January 2022
- Published by Royal Society of Chemistry (RSC)
- p. 14-23
Role of Academia: Drug Repurposing to Induce Autophagy for Treatment of Neurodegenerative Diseases
The prevalence of neurodegenerative diseases is increasing as the global population ages, and currently none of these late-onset conditions are curable. Therefore, there is an urgent need to understand the mechanisms of disease progression and to find new therapies. Most late-onset neurodegenerative disorders manifest with toxic, aggregate-prone proteins in neurons. Many of these harmful proteins have been shown to be autophagic substrates, and the induction of autophagy reduces their levels and attenuates disease phenotypes in neurodegenerative disease animal models. We and others have examined if existing drugs can be repurposed as new therapeutic agents that induce autophagy to reduce the levels of such toxic proteins. We highlight that a key component of a repurposing project is to test if the drug exposures at conventional doses in humans enable induction of the novel potentially therapeutic repurposing pathway.
- Open Access
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100500
Transient siRNA-mediated protein knockdown in mouse followed by feeding/starving cycle and liver tissue analysis
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100500
Open AccessTransient siRNA-mediated protein knockdown in mouse followed by feeding/starving cycle and liver tissue analysis
- Open Access
- 5 May 2020
- Published by Springer Nature in Cell Discovery
- Vol. 6 (1) , 1-13
Mendelian neurodegenerative disease genes involved in autophagy
The lysosomal degradation pathway of macroautophagy (herein referred to as autophagy) plays a crucial role in cellular physiology by regulating the removal of unwanted cargoes such as protein aggregates and damaged organelles. Over the last five decades, significant progress has been made in understanding the molecular mechanisms that regulate autophagy and its roles in human physiology and diseases. These advances, together with discoveries in human genetics linking autophagy-related gene mutations to specific diseases, provide a better understanding of the mechanisms by which autophagy-dependent pathways can be potentially targeted for treating human diseases. Here, we review mutations that have been identified in genes involved in autophagy and their associations with neurodegenerative diseases.
- 5 May 2020
- Published by Springer Nature in Cell Discovery
- Vol. 6 (1) , 1-13
Open AccessMendelian neurodegenerative disease genes involved in autophagy
The lysosomal degradation pathway of macroautophagy (herein referred to as autophagy) plays a crucial role in cellular physiology by regulating the removal of unwanted cargoes such as protein aggregates and damaged organelles. Over the last five decades, significant progress has been made in understanding the molecular mechanisms that regulate autophagy and its roles in human physiology and diseases. These advances, together with discoveries in human genetics linking autophagy-related gene mutations to specific diseases, provide a better understanding of the mechanisms by which autophagy-dependent pathways can be potentially targeted for treating human diseases. Here, we review mutations that have been identified in genes involved in autophagy and their associations with neurodegenerative diseases.
- Open Access
- 24 April 2019
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 47 (11) , 5777-5791
Non-canonical translation initiation in yeast generates a cryptic pool of mitochondrial proteins
Utilization of non-AUG alternative translation start sites is most common in bacteria and viruses, but it has been also reported in other organisms. This phenomenon increases proteome complexity by allowing expression of multiple protein isoforms from a single gene. In Saccharomyces cerevisiae, a few described cases concern proteins that are translated from upstream near-cognate start codons as N-terminally extended variants that localize to mitochondria. Using bioinformatics tools, we provide compelling evidence that in yeast the potential for producing alternative protein isoforms by non-AUG translation initiation is much more prevalent than previously anticipated and may apply to as many as a few thousand proteins. Several hundreds of candidates are predicted to gain a mitochondrial targeting signal (MTS), generating an unrecognized pool of mitochondrial proteins. We confirmed mitochondrial localization of a subset of proteins previously not identified as mitochondrial, whose standard forms do not carry an MTS. Our data highlight the potential of non-canonical translation initiation in expanding the capacity of the mitochondrial proteome and possibly also other cellular features.
- 24 April 2019
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 47 (11) , 5777-5791
Open AccessNon-canonical translation initiation in yeast generates a cryptic pool of mitochondrial proteins
Utilization of non-AUG alternative translation start sites is most common in bacteria and viruses, but it has been also reported in other organisms. This phenomenon increases proteome complexity by allowing expression of multiple protein isoforms from a single gene. In Saccharomyces cerevisiae, a few described cases concern proteins that are translated from upstream near-cognate start codons as N-terminally extended variants that localize to mitochondria. Using bioinformatics tools, we provide compelling evidence that in yeast the potential for producing alternative protein isoforms by non-AUG translation initiation is much more prevalent than previously anticipated and may apply to as many as a few thousand proteins. Several hundreds of candidates are predicted to gain a mitochondrial targeting signal (MTS), generating an unrecognized pool of mitochondrial proteins. We confirmed mitochondrial localization of a subset of proteins previously not identified as mitochondrial, whose standard forms do not carry an MTS. Our data highlight the potential of non-canonical translation initiation in expanding the capacity of the mitochondrial proteome and possibly also other cellular features.
- 13 December 2018
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 26 (4) , 617-629
Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation
Autophagy is a conserved intracellular degradation pathway essential for protein homeostasis, survival and development. Defects in autophagic pathways have been connected to a variety of human diseases, including cancer and neurodegeneration. In the process of macroautophagy, cytoplasmic cargo is enclosed in a double-membrane structure and fused to the lysosome to allow for digestion and recycling of material. Autophagosome formation is primed by the ULK complex, which enables the downstream production of PI(3)P, a key lipid signalling molecule, on the phagophore membrane. The PI(3)P is generated by the PI3 kinase (PI3K) complex, consisting of the core components VPS34, VPS15 and Beclin 1. Beclin 1 is a central player in autophagy and constitutes a molecular platform for the regulation of autophagosome formation and maturation. Post-translational modifications of Beclin 1 affect its stability, interactions and ability to regulate PI3K activity, providing the cell with a plethora of strategies to fine-tune the levels of autophagy. Being such an important regulator, Beclin 1 is a potential target for therapeutic intervention and interfering with the post-translational regulation of Beclin 1 could be one way of manipulating the levels of autophagy. In this review, we provide an overview of the known post-translational modifications of Beclin 1 that govern its role in autophagy and how these modifications are maintained by input from several upstream signalling pathways. ▓
- 13 December 2018
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 26 (4) , 617-629
Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation
Autophagy is a conserved intracellular degradation pathway essential for protein homeostasis, survival and development. Defects in autophagic pathways have been connected to a variety of human diseases, including cancer and neurodegeneration. In the process of macroautophagy, cytoplasmic cargo is enclosed in a double-membrane structure and fused to the lysosome to allow for digestion and recycling of material. Autophagosome formation is primed by the ULK complex, which enables the downstream production of PI(3)P, a key lipid signalling molecule, on the phagophore membrane. The PI(3)P is generated by the PI3 kinase (PI3K) complex, consisting of the core components VPS34, VPS15 and Beclin 1. Beclin 1 is a central player in autophagy and constitutes a molecular platform for the regulation of autophagosome formation and maturation. Post-translational modifications of Beclin 1 affect its stability, interactions and ability to regulate PI3K activity, providing the cell with a plethora of strategies to fine-tune the levels of autophagy. Being such an important regulator, Beclin 1 is a potential target for therapeutic intervention and interfering with the post-translational regulation of Beclin 1 could be one way of manipulating the levels of autophagy. In this review, we provide an overview of the known post-translational modifications of Beclin 1 that govern its role in autophagy and how these modifications are maintained by input from several upstream signalling pathways. ▓
- Open Access
- 22 January 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-17
Quantitative proteomics identifies redox switches for global translation modulation by mitochondrially produced reactive oxygen species
The generation of reactive oxygen species (ROS) is inevitably linked to life. However, the precise role of ROS in signalling and specific targets is largely unknown. We perform a global proteomic analysis to delineate the yeast redoxome to a depth of more than 4,300 unique cysteine residues in over 2,200 proteins. Mapping of redox-active thiols in proteins exposed to exogenous or endogenous mitochondria-derived oxidative stress reveals ROS-sensitive sites in several components of the translation apparatus. Mitochondria are the major source of cellular ROS. We demonstrate that increased levels of intracellular ROS caused by dysfunctional mitochondria serve as a signal to attenuate global protein synthesis. Hence, we propose a universal mechanism that controls protein synthesis by inducing reversible changes in the translation machinery upon modulating the redox status of proteins involved in translation. This crosstalk between mitochondria and protein synthesis may have an important contribution to pathologies caused by dysfunctional mitochondria.
- 22 January 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-17
Open AccessQuantitative proteomics identifies redox switches for global translation modulation by mitochondrially produced reactive oxygen species
The generation of reactive oxygen species (ROS) is inevitably linked to life. However, the precise role of ROS in signalling and specific targets is largely unknown. We perform a global proteomic analysis to delineate the yeast redoxome to a depth of more than 4,300 unique cysteine residues in over 2,200 proteins. Mapping of redox-active thiols in proteins exposed to exogenous or endogenous mitochondria-derived oxidative stress reveals ROS-sensitive sites in several components of the translation apparatus. Mitochondria are the major source of cellular ROS. We demonstrate that increased levels of intracellular ROS caused by dysfunctional mitochondria serve as a signal to attenuate global protein synthesis. Hence, we propose a universal mechanism that controls protein synthesis by inducing reversible changes in the translation machinery upon modulating the redox status of proteins involved in translation. This crosstalk between mitochondria and protein synthesis may have an important contribution to pathologies caused by dysfunctional mitochondria.